Epitalon: limits of adverse-event evidence
Khavinson and colleagues’ 2003 study added epitalon to cultured human fetal fibroblasts and examined telomerase and telomeres. The inspected abstract describes a cell experiment and gives no patient adverse-event frequencies. [1]
This abstract cannot establish a clinical adverse-reaction profile or human safety for epitalon. A cell model also does not establish safety of a particular reagent batch. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Adverse events in patients | Cultured human fetal fibroblasts (cell experiment) | The abstract gives no patient adverse-event frequencies; a clinical adverse-reaction profile cannot be established from it | [1] |
References
- Khavinson VKh et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells https://doi.org/10.1023/A:1025493705728.